Daiichi Jitsugyo Co (8059) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Sep, 2025Executive summary
Achieved record-high sales and profits in FY2024, with net sales rising 18.1% to ¥221.8 billion and all income types at all-time highs; net sales surpassed ¥200 billion for the first time.
Operating income increased 44.1% to ¥13.1 billion, and profit attributable to owners of parent grew 18.5% to ¥8.84 billion.
Comprehensive income declined 26.8% year-over-year to ¥8.62 billion due to a decrease in other comprehensive income components.
Energy Solutions, Healthcare, and Automotive businesses were key contributors to growth, with significant overseas performance, especially in the Americas.
Financial highlights
Orders received rose 1.3% year-over-year to ¥206.3 billion; net sales increased 18.1% to ¥221.8 billion.
Ordinary income surged 51.0% to ¥13.6 billion; basic EPS increased by ¥43.24 to ¥278.57, reflecting a 3-for-1 stock split.
Gross profit increased to ¥37.77 billion, while SG&A expenses rose to ¥24.67 billion.
Overseas sales ratio increased, with record-high results in the Americas (+164.9%); sales in China declined.
Total assets decreased to ¥171.37 billion, while net assets increased to ¥79.85 billion.
Outlook and guidance
FY2025 forecast: orders received to rise 11.5% to ¥230 billion; net sales to slightly decrease by 0.8% to ¥220 billion.
Operating income expected to decline 8.4% to ¥12 billion; profit attributable to owners of parent to decrease 2.7% to ¥8.6 billion.
Annual dividend forecast is ¥108 per share, with a payout ratio of 40%.
ROE target remains at 10% or higher.
Latest events from Daiichi Jitsugyo Co
- Record Q3 profits and strong segment growth support an upwardly revised full-year outlook.8059
Q3 20264 Feb 2026 - Record Q2 sales and profits led to upward revisions in full-year forecasts and dividends.8059
Q2 20267 Nov 2025 - Record-high sales and profit, improved equity ratio, and strong full-year outlook.8059
Q2 20259 Sep 2025 - Record Q3 sales and profits, stock split, and strong growth across all segments.8059
Q3 20259 Sep 2025 - Record Q1 sales and profits driven by Healthcare and Automobile, but outlook is slightly cautious.8059
Q1 20269 Sep 2025 - Strong sales and profit growth, with robust outlook and improved equity ratio.8059
Q1 20259 Sep 2025